Y0001101
Interferon β-1a
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
grade
pharmaceutical primary standard
API family
interferon
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
shipped in
dry ice
storage temp.
−70°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Normand E Allaire et al.
BMC research notes, 6, 8-8 (2013-01-08)
Clinical trials offer a unique opportunity to study human disease and response to therapy in a highly controlled setting. The application of high-throughput expression profiling to peripheral blood from clinical trial subjects could facilitate the identification of transcripts that function
F Wild
Der Nervenarzt, 84(2), 202-208 (2012-12-18)
For persons covered by statutory health insurance (SHI) an increase in the number of defined daily doses (DDD) for pharmaceuticals to treat multiple sclerosis (MS) is known but so far there has been no comparable survey for private health insurance
Diego Cadavid et al.
PloS one, 8(1), e53297-e53297 (2013-01-12)
There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis. Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS).
Tae Ikeda et al.
No to hattatsu = Brain and development, 45(1), 49-52 (2013-04-19)
We report a case of a 15-year-old girl with relapsing-remitting multiple sclerosis (MS) who received cyclophosphamide pulse therapy. At the age of 5 years, she displayed symptoms such as headache and unconsciousness after varicella infection as the first episode of
Jeffrey A Cohen et al.
Lancet (London, England), 380(9856), 1819-1828 (2012-11-06)
The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service